Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock
In This Article:
Medtronic plc MDT recently shared long-term data from its SPYRAL HTN-ON MED clinical trial. The trial data showed significantly greater reductions in 24-hour ambulatory systolic blood pressure (ABPM) and office-based systolic blood pressure (OSBP) in subjects who underwent radiofrequency renal denervation with the company’s Symplicity Spyral renal denervation (RDN) system compared to sham patients at two years. The findings were presented at the 2024 Transcatheter Cardiovascular Therapeutics Conference.
The latest findings are crucial for informing the medical community about the long-term effectiveness of radiofrequency renal denervation in treating uncontrolled hypertension.
MDT’s Likely Stock Trend Following the News
Subsequent to the news, the share price of MDT moved north 0.01% to $90.60 yesterday. The latest development is likely to boost the company’s Coronary and Renal Denervation business within the Cardiovascular portfolio. With cutting-edge technologies like the Symplicity RDN system, Medtronic’s extensive investment and development efforts position it well to capitalize on this opportunity. We expect market sentiment toward MDT stock to continue to remain positive surrounding this news.
Medtronic boasts a market capitalization of $116.20 billion. The company delivered an average earnings surprise of 3.07% in the trailing four quarters.
More on Medtronic’s Favorable Trial Results
SPYRAL HTN-ON MED is a global, randomized, sham-controlled trial investigating the blood pressure-lowering effect and safety of RDN with the radiofrequency-based Symplicity Spyral RDN system in hypertensive patients who have been prescribed up to three anti-hypertensive medications. After the six-month primary endpoint assessment, the study continued to assess 24-hour ABPM and OSBP from baseline through yearly follow-ups.
The latest two-year data for the Symplicity RDN system is consistent with other long-term data, demonstrating clinically meaningful, consistent and sustained blood pressure reductions.
Data showed significant group differences in 24-hour ABPM and OSBP in favor of RDN despite significantly more medications detected in the sham group. Additionally, data revealed long-term safety with no confirmed renal artery stenosis greater than 70% in the Spyral group at two years.
Medtronic’s Business Advancements
The company intends to investigate multi-organ (hepatic and renal artery) denervation with the Symplicity Spyral catheter. The planned Global Pilot study of renal and hepatic combined denervation (SPYRAL GEMINI pilot study) will investigate the safety and efficacy of the multi-organ ablation approach in uncontrolled hypertension patients who are both on and off medications. Additionally, Medtronic anticipates expanding the GSR-DEFINE clinical trial to sites in the United States. The GSR-DEFINE trial is an extension of the Global SYMPLICITY Registry.
